ChulaCov19 mRNA vaccine Uses, Dosage, Side Effects and more
The ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US. Pre-clinical studies in mice and monkeys showed evidence that the vaccine facilitates an impressive generation of neutralizing antibodies. The next phase of this study is for phase I and II clinical trials (NCT04566276) beginning in January 2021.
| Trade Name | ChulaCov19 mRNA vaccine |
| Generic | ChulaCov19 mRNA vaccine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
